Epicrispr Secures $90 Million in Latest Funding Round

Epicrispr secured $90 million in its latest funding round, adding another data point to the FinTech funding market.

Epicrispr Raises $90 million in Funding

Epicrispr raises $90M to rewrite treatment of rare muscle disease. With EPI-321, Epicrispr is using this strategy to silence the genetic driver of facioscapulohumeral muscular dystrophy, or FSHD, a progressive neuromuscular condition.

Investors Behind the Funding

The round was backed by undisclosed investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Epicrispr operates in FinTech. Epicrispr's financing adds to recent private-market activity.

Strategic Use of Funds

Rewrite treatment of rare muscle disease.

Looking Ahead

Epicrispr raises $90M to rewrite treatment of rare muscle disease

Source reference: original announcement/article.